意大利60岁及以上人群中单价与二价mRNA加强针预防奥密克戎BA.5所致重症COVID-19的相对有效性:接种后4个月内的回顾性匹配队列研究
该回顾性匹配队列研究链接意大利疫苗接种登记与SARS-CoV-2监测系统,在2022年9月12日至2023年1月7日期间,1:1匹配60岁及以上接受第二剂加强针者与仅接受第一剂加强针至少120天者,共分析2 129 559对匹配。结果显示,针对奥密克戎BA.5所致重症COVID-19,二价原始株/BA.4-5加强针的相对疫苗有效性(rVE)在接种后14-118天为50.6%(95%CI 46.0-54.8),二价原始株/BA.1为49.3%(43.6-54.4),单价加强针为26.9%(11.8-39.3)。
要点
- 第二剂mRNA加强针可为60岁及以上人群提供针对奥密克戎BA.5所致重症COVID-19的额外保护。
- 二价原始株/BA.4-5加强针接种后14-118天rVE为50.6%(95%CI 46.0-54.8)。
- 二价原始株/BA.4-5加强针在接种后4个月时仍提供保护,尽管rVE随时间下降。
核心结论
- 这些发现提示,第二剂mRNA疫苗加强针可为60岁及以上人群提供针对奥密克戎BA.5所致重症COVID-19的额外保护。
- 尽管rVE随时间下降,但接种原始株/BA.4-5 mRNA疫苗第二剂加强针在接种后4个月时仍提供保护。
研究设计与样本
- 回顾性匹配队列研究,链接意大利疫苗接种登记与SARS-CoV-2监测系统数据。
- 2022年9月12日至2023年1月7日期间,将每名60岁及以上接受第二剂加强针者与一名仅接受第一剂加强针至少120天者按1:1匹配。
- 共分析2 129 559对匹配。
- 使用Cox比例风险模型估计风险比,并计算相对疫苗有效性(rVE)为(1-风险比)×100。
主要发现
- 针对重症COVID-19,二价原始株/BA.4-5加强针在接种后14-118天的rVE为50.6%(95%CI 46.0-54.8)。
- 二价原始株/BA.1加强针的总体rVE为49.3%(95%CI 43.6-54.4)。
- 单价加强针的总体rVE为26.9%(95%CI 11.8-39.3)。
- 对于二价原始株/BA.4-5加强针,60-79岁年龄组的总体rVE为53.6%(95%CI 46.8-59.5),80岁及以上年龄组为48.3%(95%CI 41.9-54.0),未观察到相关差异。
关键数值与推荐
- 二价原始株/BA.4-5加强针接种后14-118天rVE为50.6%(95%CI 46.0-54.8)。
- 二价原始株/BA.1加强针总体rVE为49.3%(95%CI 43.6-54.4)。
- 单价加强针总体rVE为26.9%(95%CI 11.8-39.3)。
- 60-79岁年龄组二价原始株/BA.4-5加强针总体rVE为53.6%(95%CI 46.8-59.5),80岁及以上年龄组为48.3%(95%CI 41.9-54.0)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,第二剂mRNA疫苗加强针可为60岁及以上人群提供针对奥密克戎BA.5所致重症COVID-19的额外保护。
- 作者指出,尽管rVE随时间下降,但接种原始株/BA.4-5 mRNA疫苗第二剂加强针在接种后4个月时仍提供保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited evidence is available on the additional protection conferred by second mRNA vaccine boosters against severe COVID-19 caused by omicron BA.5 infection, and whether the adapted bivalent boosters provide additional protection compared with the monovalent ones. In this study, we aimed to estimate the relative effectiveness of a second booster with monovalent or bivalent mRNA vaccines against severe COVID-19 in Italy. METHODS: Linking data from the Italian vaccination registry and the SARS-CoV-2 surveillance system, between Sept 12, 2022, and Jan 7, 2023, we matched 1:1 each person aged 60 years or older receiving a second booster with a person who had received the first booster only at least 120 days earlier. We used hazard ratios, estimated through Cox proportional hazard models, to compare the hazard of severe COVID-19 between the first booster group and each type of second booster (monovalent mRNA vaccine targeting the original strain of SARS-CoV-2, bivalent mRNA vaccine targeting the original strain plus omicron BA.1 [bivalent original/BA.1], and bivalent mRNA vaccine targeting the original strain plus omicron BA.4 and BA.5 [bivalent original/BA.4-5]). Relative vaccine effectiveness (rVE) was calculated as (1-hazard ratio) × 100. FINDINGS: We analysed a total of 2 129 559 matched pairs. The estimated rVE against severe COVID-19 with the bivalent original/BA.4-5 booster was 50·6% (95% CI 46·0-54·8) in the overall time interval 14-118 days post-administration. Overall, rVE was 49·3% (43·6-54·4) for the bivalent original/BA.1 booster and 26·9% (11·8-39·3) for the monovalent booster. For the bivalent original/BA.4-5 booster, we did not observe relevant differences in rVE between the 60-79-year age group (overall, 53·6%; 46·8-59·5) and those aged 80 years or older (overall, 48·3%; 41·9-54·0). INTERPRETATION: These findings suggest that a second booster with mRNA vaccines provides additional protection against severe COVID-19 due to omicron BA.5 (the predominant circulating subvariant in Italy during the study period) in people aged 60 years or older. Although rVE decreased over time, a second booster with the original/BA.4-5 mRNA vaccine, currently the most used in Italy, was found to be still providing protection 4 months post-administration. FUNDING: NextGenerationEU-MUR-PNRR Extended Partnership initiative on Emerging Infectious Diseases (project number PE00000007, INF-ACT). TRANSLATION: For the Italian translation of the abstract see Supplementary Materials section.
引用
- Mateo-Urdiales A, Sacco C, Fotakis EA, et al. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. Lancet Infect Dis. 2023. PMID: 37478877. doi:10.1016/S1473-3099(23)00374-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。